• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Acorda Therapeutics

edit

Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The first product for which the Company completed clinical development, Ampyra (dalfampridine) Extended Release Tablets (Ampyra), was approved by the United States Food and Drug Administration (FDA) in January 2010, as a treatment to improve walking in patients with MS. Ampyra is an extended-release tablet formulation of dalfampridine (4-aminopyridine (4-AP)), which was previously referred to as fampridine. Acorda’s marketed product, Zanaflex Capsules, is approved by the FDA as a short-acting drug for the management of spasticity.

Recent Milestones

edit

• 
  Acorda Therapeutics acquired Neuronex for $130M. (2/17/12)
  Posted 2/17/12 at 6:32pm via dowjones.com
• 
  Acorda Therapeutics — Acorda snags Ph2 neurological trauma program in $35M deal (7/1/11)
  Posted 7/3/11 at 6:24pm via fiercebiotech.com
• 
  Went public with stock symbol NASDAQ:ACOR.
  Posted 7/3/11 at 6:23pm
• 
  Acorda Therapeutics added Ron Cohen as President and CEO.
  Posted 7/3/11 at 6:23pm
• 
  Acorda Therapeutics added Jennifer Burstein as Vice President, Finance.
  Posted 7/3/11 at 6:23pm

Videos

Screenshots

edit

Stock Price

Sources

1. Acorda Thera Acquiring Neuronex In Deal Potentially Worth Over $130M (fis.dowjones.com) [edit]
Acorda snags Ph2 neurological trauma program in $35M deal (fiercebiotech.com) [edit]